Endothelial protocadherins in vascular development and disease
- Institution
- Yale University, CT
- Principal investigator
- Martin A Schwartz
- Funding
- $776K
- Duration
- 2025–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Transcription factors Klf2 and 4 are strongly induced in vascular endothelial cells (ECs) by fluid shear stress from blood flow, where they confer vascular stability and suppress the inflammatory pathways and genes responsible for atherosclerosis and other diseases that involve vascular inflammation. This application is based on our recent discovery that gamma protocadherins (Pcdhg) block Notch-dependent transcription and thus suppress expression Klf2/4 in ECs, which facilitates vascular inflammation and disease. Pcdhg knockout in endothelial cells limits atherosclerosis in mice and alters vascular morphogenesis in the postnatal retina. Based on our findings, we hypothesize that Pcdhg is a key regulator of vascular stability and resilience that contributes to vascular morphogenesis but whose inhibition provides a novel means of treating vascular inflammation without compromising host defense against pathogens. To test these hypotheses, we propose to: 1) Determine the effects in mice of knocking out the Pcdhg cluster in ECs or inhibiting the key isoform Pcdhga9, examining multiple models of vascular inflammation. 2) Elucidate the mechanism by which Pcdhg controls Klf2/4 expression, focusing on interactions with the Notch pathway. 3) Characterize the effects of EC Pcdhg knockout on angiogenesis and arteriogenesis in the postnatal retina and determine the molecular mechanisms of observed effects.
Research team
- Anne Christine EichmannPI
- Martin A SchwartzPI
LOADING MOONBASE SCORE
Questions for Yale University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Yale UniversityNot yet scored
Roles of Fibrillin-1 and Fibronectin in Thoracic Aortopathy - Adhesion Receptor Signaling
Martin A Schwartz · $358K · 2025–2029
- NIH · Yale UniversityNot yet scored
A QUANTITATIVE, PREDICTIVE MODEL OF VASCULAR REMODELING IN HEALTH AND DISEASE
Martin A Schwartz · $670K · 2024–2028
- NIH · Yale UniversityNot yet scored
Lymphatic drainage dysfunction in chronic hypertension
Helene D Benveniste · $747K · 2024–2028